JP7308765B2 - 増殖性障害の治療に使用される三環式化合物 - Google Patents

増殖性障害の治療に使用される三環式化合物 Download PDF

Info

Publication number
JP7308765B2
JP7308765B2 JP2019571789A JP2019571789A JP7308765B2 JP 7308765 B2 JP7308765 B2 JP 7308765B2 JP 2019571789 A JP2019571789 A JP 2019571789A JP 2019571789 A JP2019571789 A JP 2019571789A JP 7308765 B2 JP7308765 B2 JP 7308765B2
Authority
JP
Japan
Prior art keywords
alkyl
propyl
pyrido
cycloalkyl
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019571789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510092A5 (enExample
JP2020510092A (ja
Inventor
アンドリュー・モーリー
レベッカ・ミラー
ニコラス・ラ・タンゲ
Original Assignee
アルゴノート・セラピューティクス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルゴノート・セラピューティクス・リミテッド filed Critical アルゴノート・セラピューティクス・リミテッド
Publication of JP2020510092A publication Critical patent/JP2020510092A/ja
Publication of JP2020510092A5 publication Critical patent/JP2020510092A5/ja
Application granted granted Critical
Publication of JP7308765B2 publication Critical patent/JP7308765B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019571789A 2017-03-17 2018-03-16 増殖性障害の治療に使用される三環式化合物 Active JP7308765B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1704325.8A GB201704325D0 (en) 2017-03-17 2017-03-17 Compounds
GB1704325.8 2017-03-17
PCT/EP2018/056675 WO2018167276A1 (en) 2017-03-17 2018-03-16 Tricyclic compounds for use in treatment of proliferative disorders

Publications (3)

Publication Number Publication Date
JP2020510092A JP2020510092A (ja) 2020-04-02
JP2020510092A5 JP2020510092A5 (enExample) 2021-04-22
JP7308765B2 true JP7308765B2 (ja) 2023-07-14

Family

ID=58688220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571789A Active JP7308765B2 (ja) 2017-03-17 2018-03-16 増殖性障害の治療に使用される三環式化合物

Country Status (9)

Country Link
US (1) US11274098B2 (enExample)
EP (1) EP3596073B1 (enExample)
JP (1) JP7308765B2 (enExample)
KR (1) KR102604942B1 (enExample)
CN (1) CN110621675B (enExample)
CA (1) CA3056726A1 (enExample)
ES (1) ES2925115T3 (enExample)
GB (1) GB201704325D0 (enExample)
WO (1) WO2018167276A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
KR102282712B1 (ko) * 2019-08-09 2021-07-27 한국화학연구원 신규한 피리미딘 설폰아마이드 유도체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
WO2021029450A1 (ko) * 2019-08-09 2021-02-18 한국화학연구원 신규한 피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물
KR102278691B1 (ko) * 2019-08-09 2021-07-16 한국화학연구원 신규한 피리미딘 설폰아마이드 유도체
WO2021066578A1 (ko) 2019-10-02 2021-04-08 에스케이바이오팜 주식회사 바이사이클릭 화합물 및 이의 용도
CN111454260B (zh) * 2020-05-25 2023-02-28 贵州大学 一类含异丙醇胺亚结构的1，2，3，4-四氢-β-咔啉类化合物及其制备方法和应用
CN111892593B (zh) * 2020-08-19 2021-11-16 南通大学 一种8-甲氧基-5H-吡啶并[4,3-b]吲哚及其合成方法
CN117062816A (zh) * 2021-02-04 2023-11-14 美国安进公司 三环-酰胺-双环prmt5抑制剂
CN113105517B (zh) * 2021-04-10 2022-03-01 台州仙琚药业有限公司 雄甾-1,4,9-三烯-3,17-二酮的合成方法
GB202108383D0 (en) * 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic
CN115521306B (zh) * 2022-09-26 2024-03-26 贵州大学 一种1,2,3,4-四氢-β-咔啉衍生物及其制备方法和应用
CN117088891B (zh) * 2023-07-13 2026-06-16 浙江大学 含四氢苯并[4,5]呋喃[2,3-c]吡啶类羟肟酸化合物及其制备方法和应用
CN121226371B (zh) * 2025-10-28 2026-07-14 百色学院 四氢吡嗪[1,2-a]吲哚类组蛋白去乙酰化酶抑制剂及其制备方法与应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505115A (ja) 1997-04-08 2000-04-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １，２，３，４―テトラヒドロ―ベンゾフロ［３，２―ｃ］ピリジン誘導体
JP2001515899A (ja) 1997-09-08 2001-09-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テトラヒドロガンマ−カルボリン類
JP2012512871A (ja) 2008-12-18 2012-06-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 三環式アザインドール
WO2015181063A1 (en) 2014-05-26 2015-12-03 Bayer Pharma Aktiengesellschaft Substituted tetrahydropyridothienopyrimidines
WO2016022605A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505022A (ja) 2013-01-14 2016-02-18 イーエヌティー アソシエイツ オブ ロス アラモス，エルエルシー ハチミツ鼻洗浄剤
JP2016516829A (ja) 2013-04-23 2016-06-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ピラジノ［１，２−ａ］インドール化合物、その調製および医薬としての使用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317524A (en) * 1965-02-04 1967-05-02 American Home Prod Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
US3687961A (en) * 1971-05-03 1972-08-29 Abbott Lab 8-fluoro-2-{8 3-(4-fluorophenylanilinopropyl{9 -gamma-carboline
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
DE2854014A1 (de) * 1978-12-14 1980-07-03 Troponwerke Gmbh & Co Kg 7,8,9,10-tetrahydrothieno eckige klammer auf 3,2-e eckige klammer zu pyrido eckige klammer auf 4,3-b eckige klammer zu indole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4719211A (en) 1984-05-01 1988-01-12 American Home Products Corporation 2,3,4,9-tetrahydro-2-heteroarylalkyl-1H-pyrido(3,4-B)indoles having antihypertensive properties
SU1248223A1 (ru) * 1985-01-07 1995-09-20 Научно-Исследовательский Институт По Биологическим Испытаниям Химических Соединений ДИГИДРОХЛОРИД 2-(3-ИЗОПРОПИЛАМИНО-2-ГИДРОКСИПРОПИЛ)-1,2,3,4-ТЕТРАГИДРО- β -КАРБОЛИНА, ОБЛАДАЮЩИЙ АНТИАЛКОГОЛЬНЫМ И ПСИХОТРОПНЫМ ДЕЙСТВИЕМ
US4663456A (en) * 1985-09-16 1987-05-05 American Home Products Corporation 2-(substituted piperazinylalkyl)β-carbolines useful in treatment of psychological disorders
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
NZ555491A (en) 2005-01-03 2010-01-29 Univ Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
US20070213359A1 (en) 2005-12-30 2007-09-13 Acadia Pharmaceuticals Inc. Bicyclic-nitrogen compounds as modulators of ghrelin receptor and uses thereof
JP2016505002A (ja) * 2012-12-21 2016-02-18 エピザイム，インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
JP6388456B2 (ja) 2013-06-28 2018-09-12 アルツプロテクト 神経変性疾患の治療に使用可能なカルボリン化合物
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
EP3160466A4 (en) * 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000505115A (ja) 1997-04-08 2000-04-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １，２，３，４―テトラヒドロ―ベンゾフロ［３，２―ｃ］ピリジン誘導体
JP2001515899A (ja) 1997-09-08 2001-09-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テトラヒドロガンマ−カルボリン類
JP2012512871A (ja) 2008-12-18 2012-06-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 三環式アザインドール
JP2016505022A (ja) 2013-01-14 2016-02-18 イーエヌティー アソシエイツ オブ ロス アラモス，エルエルシー ハチミツ鼻洗浄剤
JP2016516829A (ja) 2013-04-23 2016-06-09 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ ピラジノ［１，２−ａ］インドール化合物、その調製および医薬としての使用
WO2015181063A1 (en) 2014-05-26 2015-12-03 Bayer Pharma Aktiengesellschaft Substituted tetrahydropyridothienopyrimidines
WO2016022605A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ChemBioChem，2004年，5，508-518
J. Med. Chem.，1986年，29，8-19
J. Med. Chem.，2012年，55，639-651
REGISTRY（STN）［online］，2004年，767617-75-4

Also Published As

Publication number Publication date
US11274098B2 (en) 2022-03-15
GB201704325D0 (en) 2017-05-03
CN110621675A (zh) 2019-12-27
US20200325132A1 (en) 2020-10-15
CN110621675B (zh) 2023-09-19
ES2925115T3 (es) 2022-10-13
CA3056726A1 (en) 2018-09-20
EP3596073A1 (en) 2020-01-22
EP3596073B1 (en) 2022-05-11
KR102604942B1 (ko) 2023-11-21
WO2018167276A1 (en) 2018-09-20
KR20190129071A (ko) 2019-11-19
JP2020510092A (ja) 2020-04-02

Similar Documents

Publication Publication Date Title
KR102604942B1 (ko) 증식성 장애의 치료에 사용하기 위한 트리사이클릭 화합물
JP7211982B2 (ja) Ｐｒｍｔ５媒介性障害の治療又は予防に有用な化合物
CN112094269B (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
ES2975661T3 (es) Inhibidores de BCL6 derivados de la 2-quinolona
US20250236624A1 (en) Heterocyclic Compounds as RET Kinase Inhibitors
US9371319B2 (en) Pyrrolopyridineamino derivatives as MPS1 inhibitors
AU2008339572B2 (en) Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
JP7747666B2 (ja) がん治療のためのｍｌｈ１および／またはｐｍｓ２の阻害剤
KR20250153866A (ko) Dna 중합효소 세타 억제제
US20230045929A1 (en) Isoquinoline derivatives as sik2 inhibitors
ES2877140T3 (es) Derivados de pirimidinona como inhibidores de Cdc7
US12509457B2 (en) Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2
ES2845048T3 (es) Preparación y usos de derivados de pirimidinona
WO2025104043A1 (en) Novel compounds, compositions and therapeutic uses thereof
JP2024543183A (ja) 阻害剤化合物
RU2858287C2 (ru) Полигетероциклические соединения в качестве ингибиторов mettl3
BR112019019358B1 (pt) Compostos, composição farmacêutica, uso dos referidos compostos, método in vitro para alterar a expressão gênica em uma célula e combinação compreendendo um composto

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210315

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220914

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230412

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230412

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230502

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230704

R150 Certificate of patent or registration of utility model

Ref document number: 7308765

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250